Minocycline

CHEMBL1434 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
457.5 g/mol
LogP
-0.6
Phase
4

This broad-spectrum antibiotic belongs to the tetracycline family and works by preventing bacteria from making the proteins they need to survive. It is used to treat a wide range of bacterial infections including acne, respiratory infections, and certain sexually transmitted diseases.

분자량

457.5000 g/mol

LogP

-0.60

TPSA

165.00 Ų

리핀스키 5의 법칙

통과

치료 영역

작용 기전

Binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This inhibits bacterial protein synthesis in a bacteriostatic manner.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This inhibits bacterial protein synthesis in a bacteriostatic manner.

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O

InChI

InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1

Molecular Formula

C23H27N3O7

HBD / HBA

5 / 9

회전 가능 결합

3

무거운 원자

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This broad-spectrum antibiotic belongs to the tetracycline family and works by preventing bacteria from making the proteins they need to survive. It is used to treat a wide range of bacterial infections including acne, respiratory infections, and certain sexually transmitted diseases.

Binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This inhibits bacterial protein synthesis in a bacteriostatic manner.

Yes, Minocycline is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1434. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 54675783. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.